Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
RA Capital Management and affiliated funds filed Amendment No. 12 to their Schedule 13D reporting that their ownership in Werewolf Therapeutics common stock has fallen below the five percent threshold.
The reporting group now beneficially owns 1,985,541 shares, or 4.1% of the common stock, based on 48,596,817 shares outstanding as of May 1, 2026. Most of these shares, 1,853,646, are held by RA Capital Healthcare Fund, L.P., with an additional 131,895 shares held by RA Capital Nexus Fund II, L.P.
The funds recently executed several open market sales between June 29 and July 2, 2026, at weighted average prices ranging from $0.30 to $0.36 per share. The filing states the group ceased to be beneficial owners of more than five percent of Werewolf’s common stock on June 30, 2026, an important regulatory threshold for large shareholders.
Werewolf Therapeutics director Luke Evnin reported that affiliated investment entities sold 157,084 shares of Werewolf Therapeutics common stock in an open-market transaction at a weighted average price of $0.30 per share. The sales were executed on behalf of several MPM-managed entities under a Rule 10b5-1 trading plan dated March 26, 2026. Following the transactions, these entities together held 143,199 shares indirectly associated with Evnin, and he disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.
RA Capital Management and related funds filed Amendment No. 11 to report their current stake in Werewolf Therapeutics, Inc. The reporting persons collectively beneficially own 2,915,742 shares of common stock, representing 6.0% of the company.
The ownership includes 2,721,635 shares held by RA Capital Healthcare Fund, L.P. and 194,107 shares held by RA Capital Nexus Fund II, L.P. All voting and investment power over these shares has been delegated to RA Capital. Recent activity includes a series of open market sales between $0.32 and $0.38 per share on multiple days in late June 2026. The reported percentages are based on 48,596,817 shares outstanding as of May 1, 2026.
RA Capital Management and related entities filed Amendment No. 10 to their Schedule 13D/A on Werewolf Therapeutics, Inc. common stock, updating their ownership and recent trading. The reporting persons beneficially own 3,654,307 shares, representing 7.5% of the company’s common stock, based on 48,596,817 shares outstanding as of May 1, 2026.
The ownership includes 3,411,559 shares held by RA Capital Healthcare Fund, L.P. and 242,748 shares held by RA Capital Nexus Fund II, L.P., over which RA Capital has voting and dispositive power. The funds reported multiple open market sales between June 16 and June 22, 2026 at weighted average prices around $0.35–$0.37 per share.